Summary
No substantive FDA-label adherence for VANDAZOLE could be evaluated because the provided text contains only a list of general metronidazole statements and does not evaluate any specific AI-generated response claims against VANDAZOLE (metronidazole gel 0.75%) labeling.
Category Scores
Accurate Statements
The active ingredient of Vandazole is usually metronidazole.
Supported by Section 11 DESCRIPTION: VANDAZOLE (metronidazole gel, USP) is a vaginal dosage form containing metronidazole.
Vaginal products containing metronidazole can cause local irritation or discomfort.
Partially supported by Section 6.2 (other metronidazole formulations): topical/dermal formulations report skin irritation; label excerpt does not explicitly state local irritation for VANDAZOLE, but indicates irritation-type effects across formulations.
Unsupported Statements
Vandazole most commonly refers to metronidazole.
Label excerpt identifies VANDAZOLE as metronidazole gel, but does not support the phrasing 'most commonly refers'.
Depending on the form of metronidazole (e.g., tablets or vaginal gel/cream), it is used for bacterial infections and specific vaginal infections.
Label excerpt provided only states VANDAZOLE indication for bacterial vaginosis; it does not support general, cross-form indication statements.
Depending on the form of metronidazole, it is used for certain intestinal or anaerobic infections.
No such indication is present in the provided VANDAZOLE label excerpt.
Oral tablets of metronidazole are typically used for systemic infections.
No oral tablet/systemic infection guidance is provided in the provided VANDAZOLE label excerpt.
Oral tablets of metronidazole include infections caused by anaerobic bacteria or certain parasites.
Not supported by the provided VANDAZOLE labeling excerpt.
Vaginal formulations of metronidazole (gel/cream) are used for vaginal bacterial infections.
The label excerpt specifically indicates bacterial vaginosis in post-menarchal females; it does not broadly support 'vaginal bacterial infections' for all vaginal formulations.
Vaginal formulations of metronidazole are used for related gynecologic infections depending on the exact product label and strength.
The provided VANDAZOLE label excerpt does not support gynecologic infections beyond bacterial vaginosis.
Metronidazole kills susceptible organisms by disrupting their ability to function and replicate.
Label excerpt does not provide this mechanism description.
Metronidazole targets anaerobic bacteria more effectively than many other antibiotics.
Label excerpt provided does not support comparative effectiveness claims.
Metronidazole targets certain parasites more effectively than many other antibiotics.
Label excerpt provided does not support comparative antiparasitic effectiveness claims.
Common side effects of metronidazole can include stomach upset.
For VANDAZOLE, the provided adverse reactions list includes nausea (3%) and abdominal pain (5%), but 'stomach upset' is not directly stated.
Common side effects of metronidazole can include a metallic taste.
The provided VANDAZOLE label excerpt mentions 'unusual taste' with other metronidazole formulations, but 'metallic taste' for VANDAZOLE is not supported.
Serious reactions to metronidazole are uncommon but can include allergy.
The provided VANDAZOLE label excerpt does not support 'uncommon' or define seriousness frequency for allergy.
Extra caution is needed with metronidazole in people with a history of medication allergy to metronidazole or related drugs.
While hypersensitivity is a contraindication, the provided excerpt does not support the generalized 'extra caution' phrasing (it is a contraindication specifically in patients with history of hypersensitivity).
Extra caution is needed with metronidazole in people with liver disease because dosing may need adjustment.
No liver-disease dosing adjustment guidance is included in the provided label excerpts.
Use of metronidazole in pregnancy or breastfeeding depends on the condition and clinician guidance.
Label excerpt provided states available pregnancy data have not established risk; lactation guidance is specific (pump and discard for 48 hours after last dose). It does not support generalized 'depends on condition and clinician guidance'.
Concurrent medications may interact with metronidazole.
The label excerpt provides specific interactions (disulfiram, alcohol, warfarin, lithium, cimetidine), but does not support broad 'may interact' without specifics.
Contradictions
Low
AI Statement
Drinking alcohol during metronidazole treatment can trigger unpleasant reactions such as nausea.
Label Reference
Section 4.3 Interaction with Alcohol / Section 17 Patient Counseling Information (avoid alcohol during and for at least 3 days after therapy). The excerpt does not specify nausea as a reaction.
Low
AI Statement
Drinking alcohol during metronidazole treatment can trigger unpleasant reactions such as flushing.
Label Reference
Section 4.3 Interaction with Alcohol (disulfiram-like reaction described), but provided excerpt does not list flushing.
Low
AI Statement
Drinking alcohol during metronidazole treatment can trigger unpleasant reactions such as vomiting.
Label Reference
Section 4.3 Interaction with Alcohol (disulfiram-like reaction described), but provided excerpt does not list vomiting.
Low
AI Statement
Many metronidazole product instructions advise avoiding alcohol during treatment and for a short period after the last dose.
Label Reference
VANDAZOLE label specifically: discontinue alcohol for at least three days after therapy (Section 4.3). The statement is vague and not specific to 'at least three days'.
Important Omissions
VANDAZOLE-specific indication limitation (treatment of bacterial vaginosis in post-menarchal females) is not clearly stated in the provided AI claim list.
Importance:
Moderate
VANDAZOLE-specific dosage instructions: one applicator intravaginally once daily for 5 days, bedtime administration; not for ophthalmic, dermal, or oral use.
Importance:
Moderate
Key VANDAZOLE contraindication details for hypersensitivity and disulfiram (including timing within last two weeks) were not explicitly linked to VANDAZOLE use in the provided claim list.
Importance:
Moderate
VANDAZOLE-specific drug interaction monitoring items (e.g., prothrombin time/INR with coumarin anticoagulants; lithium serum concentrations with lithium; cimetidine note) are not included.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims are largely general and not clearly mapped to VANDAZOLE-specific labeling requirements; where alcohol reaction details are vague/unsupported, the immediate risk is limited by lack of direct dosing/contraindication misdirection in the provided list, but VANDAZOLE-specific guidance and interactions/contraindications are omitted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Many statements are generic metronidazole information not supported by the provided VANDAZOLE (0.75% vaginal gel) prescribing information excerpts; VANDAZOLE-specific indication, dosing, and key safety details are not clearly and fully covered.
Suggested Improvement
Restrict claims to VANDAZOLE-labeled content: bacterial vaginosis indication in post-menarchal females; intravaginal one applicator once daily for 5 days at bedtime; contraindications (hypersensitivity; disulfiram within 2 weeks); alcohol avoidance during and at least 3 days after therapy; and specific interaction counseling (oral anticoagulants, lithium) as stated in the label.